Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GeneDx Holdings Corp. (WGSWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: WGSWW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.81% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.01 | 52 Weeks Range 0.02 - 0.34 | Updated Date 05/17/2025 |
52 Weeks Range 0.02 - 0.34 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.69% | Operating Margin (TTM) -5.22% |
Management Effectiveness
Return on Assets (TTM) -1.84% | Return on Equity (TTM) -16.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 19433395 |
Shares Outstanding - | Shares Floating 19433395 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
GeneDx Holdings Corp.
Company Overview
History and Background
GeneDx Holdings Corp. (WGS) was founded in 2000 and specializes in genomic testing. It aims to provide accessible and actionable genomic information to improve patient care.
Core Business Areas
- Exome Sequencing: Provides comprehensive exome sequencing to identify genetic variants associated with various diseases.
- Genome Sequencing: Offers full genome sequencing services to provide a broader view of an individual's genetic makeup.
- Rare Disease Diagnosis: Focuses on diagnosing rare genetic diseases using advanced genomic technologies.
- Carrier Screening: Offers carrier screening tests to identify individuals who carry genes for specific inherited disorders.
Leadership and Structure
GeneDx is led by a management team with experience in genomics and healthcare. The organizational structure focuses on research, development, and clinical applications of genomic technologies.
Top Products and Market Share
Key Offerings
- Whole Exome Sequencing (WES): Offers comprehensive analysis of protein-coding regions of the genome. Competitors include Invitae (NVTA) and Myriad Genetics (MYGN). No specific market share data available, but this is a core service driving revenue.
- Whole Genome Sequencing (WGS): Provides complete sequencing of the entire genome. Competitors include Illumina (ILMN) and Pacific Biosciences (PACB). Demand is growing but no specific market share data available. Revenue contributions less than WES currently.
- GeneDx Xomeu00ae Test: A comprehensive whole exome sequencing test designed to identify genetic causes of rare diseases and other inherited conditions. The market is composed of various genetic testing labs. Competitors: CENTOGENE, Blueprint Genetics (acquired by Roche).
Market Dynamics
Industry Overview
The genomic testing market is rapidly growing due to technological advancements and increasing demand for personalized medicine. Precision medicine initiatives and greater awareness of genetic predispositions are driving market expansion.
Positioning
GeneDx is positioned as a leader in rare disease diagnosis through genomic testing. Its competitive advantages include extensive experience, comprehensive test offerings, and a focus on accuracy and clinical utility.
Total Addressable Market (TAM)
The global genomic testing market is projected to reach over $62.9 billion by 2032. GeneDx is strategically positioned to capture a significant share of this growing market by expanding its test offerings and geographic reach.
Upturn SWOT Analysis
Strengths
- Deep expertise in genomic sequencing and interpretation
- Strong reputation in rare disease diagnosis
- Comprehensive test menu
- Focus on clinical utility and accuracy
Weaknesses
- High costs associated with genomic sequencing
- Reimbursement challenges from payers
- Competition from larger, more diversified companies
- Limited marketing and sales presence compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing new genomic tests for various diseases
- Partnering with pharmaceutical companies for drug development
- Leveraging artificial intelligence for data analysis and interpretation
Threats
- Decreasing reimbursement rates for genomic tests
- Increasing competition from new entrants
- Regulatory changes affecting genomic testing
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- Invitae (NVTA)
- Myriad Genetics (MYGN)
- Illumina (ILMN)
- Pacific Biosciences (PACB)
- CENTOGENE (N/A)
- Roche (ROG.SW)
Competitive Landscape
GeneDx competes in a crowded market, with strengths in rare disease diagnosis. Competition is intense, particularly on pricing and test menu breadth. GeneDx needs to continually innovate and focus on clinical utility to maintain its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Prior to going private, GeneDx showed revenue growth alongside ongoing net losses
Future Projections: Future growth projections are unavailable as GeneDx is now a private entity.
Recent Initiatives: Recent initiatives have likely focused on optimizing operations and expanding service offerings as a private company, but specific details are not publicly available.
Summary
GeneDx is a company specializing in genomic testing, particularly for rare diseases. It competes in a growing market against larger, more diversified companies. It faces threats from reimbursement challenges and competition but has opportunities to expand its test offerings and geographic reach. Financial performance and shareholder returns were poor before going private.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Prior Public Filings (SEC)
- Market Research Reports
- Industry Analysis
Disclaimers:
Data and analysis are based on publicly available information and analyst estimates. Market share data is approximate. This analysis is for informational purposes only and should not be considered investment advice. This information might not be entirely up-to-date, given the company is private.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeneDx Holdings Corp.
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 2020-10-29 | President, CEO & Director Ms. Katherine A. Stueland | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://www.genedx.com |
Full time employees 1000 | Website https://www.genedx.com | ||
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.